168 related articles for article (PubMed ID: 35241087)
1. Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial.
Qin X; Ji D; Gu W; Han W; Luo H; Du C; Zou Q; Sun Z; He C; Zhu S; Chong T; Yao X; Wan B; Yang X; Bai A; Jin C; Zou J; Ye D
BMC Med; 2022 Mar; 20(1):84. PubMed ID: 35241087
[TBL] [Abstract][Full Text] [Related]
2. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
Fizazi K; Massard C; Bono P; Jones R; Kataja V; James N; Garcia JA; Protheroe A; Tammela TL; Elliott T; Mattila L; Aspegren J; Vuorela A; Langmuir P; Mustonen M;
Lancet Oncol; 2014 Aug; 15(9):975-85. PubMed ID: 24974051
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.
Rathkopf DE; Morris MJ; Fox JJ; Danila DC; Slovin SF; Hager JH; Rix PJ; Chow Maneval E; Chen I; Gönen M; Fleisher M; Larson SM; Sawyers CL; Scher HI
J Clin Oncol; 2013 Oct; 31(28):3525-30. PubMed ID: 24002508
[TBL] [Abstract][Full Text] [Related]
4. ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer.
Peltola KJ; Bono P; Jones RH; Vjaters E; Nykänen P; Vuorela A; Oksala R; Pohjanjousi P; Mustonen MVJ; Fizazi K; Massard C
Eur Urol Focus; 2020 Jan; 6(1):63-70. PubMed ID: 30194031
[TBL] [Abstract][Full Text] [Related]
5. Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.
Higano CS; Beer TM; Taplin ME; Efstathiou E; Hirmand M; Forer D; Scher HI
Eur Urol; 2015 Nov; 68(5):795-801. PubMed ID: 25698064
[TBL] [Abstract][Full Text] [Related]
6. Preclinical profile and phase I clinical trial of a novel androgen receptor antagonist GT0918 in castration-resistant prostate cancer.
Zhou T; Xu W; Zhang W; Sun Y; Yan H; Gao X; Wang F; Zhou Q; Hou J; Ren S; Yang Q; Yang B; Xu C; Zhou Q; Wang M; Chen C; Sun Y
Eur J Cancer; 2020 Jul; 134():29-40. PubMed ID: 32460179
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer.
Serritella AV; Shevrin D; Heath EI; Wade JL; Martinez E; Anderson A; Schonhoft J; Chu YL; Karrison T; Stadler WM; Szmulewitz RZ
Clin Cancer Res; 2022 Apr; 28(8):1549-1559. PubMed ID: 35110415
[TBL] [Abstract][Full Text] [Related]
8. An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer.
Tsuchiya T; Imanaka K; Iwaki Y; Oyama R; Hashine K; Yamaguchi A; Uemura H
Int J Clin Oncol; 2019 Dec; 24(12):1596-1604. PubMed ID: 31446511
[TBL] [Abstract][Full Text] [Related]
9. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.
Scher HI; Beer TM; Higano CS; Anand A; Taplin ME; Efstathiou E; Rathkopf D; Shelkey J; Yu EY; Alumkal J; Hung D; Hirmand M; Seely L; Morris MJ; Danila DC; Humm J; Larson S; Fleisher M; Sawyers CL;
Lancet; 2010 Apr; 375(9724):1437-46. PubMed ID: 20398925
[TBL] [Abstract][Full Text] [Related]
10. [Enzalutamide-a novel androgen receptor inhibitor that provides treatment options for patients with castration-resistant prostate cancer].
Maeda H; Saito A
Gan To Kagaku Ryoho; 2014 Jul; 41(7):805-10. PubMed ID: 25131864
[TBL] [Abstract][Full Text] [Related]
11. Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial.
Fizazi K; Massard C; Bono P; Kataja V; James N; Tammela TL; Joensuu H; Aspegren J; Mustonen M
Eur Urol Focus; 2017 Dec; 3(6):606-614. PubMed ID: 28753849
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer.
Nakabayashi M; Werner L; Courtney KD; Buckle G; Oh WK; Bubley GJ; Hayes JH; Weckstein D; Elfiky A; Sims DM; Kantoff PW; Taplin ME
BJU Int; 2012 Dec; 110(11):1729-35. PubMed ID: 22928480
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study.
Loriot Y; Fizazi K; Jones RJ; Van den Brande J; Molife RL; Omlin A; James ND; Baskin-Bey E; Heeringa M; Baron B; Holtkamp GM; Ouatas T; De Bono JS
Invest New Drugs; 2014 Oct; 32(5):995-1004. PubMed ID: 24771350
[TBL] [Abstract][Full Text] [Related]
14. Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of
Tagawa ST; Thomas C; Sartor AO; Sun M; Stangl-Kremser J; Bissassar M; Vallabhajosula S; Huicochea Castellanos S; Nauseef JT; Sternberg CN; Molina A; Ballman K; Nanus DM; Osborne JR; Bander NH
J Clin Oncol; 2024 Mar; 42(7):842-851. PubMed ID: 37922438
[TBL] [Abstract][Full Text] [Related]
15. Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.
Massard C; Chi KN; Castellano D; de Bono J; Gravis G; Dirix L; Machiels JP; Mita A; Mellado B; Turri S; Maier J; Csonka D; Chakravartty A; Fizazi K
Eur J Cancer; 2017 May; 76():36-44. PubMed ID: 28282611
[TBL] [Abstract][Full Text] [Related]
16. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
Fizazi K; Smith MR; Tombal B
Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
[TBL] [Abstract][Full Text] [Related]
17. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
Fallah J; Zhang L; Amatya A; Gong Y; King-Kallimanis B; Bhatnagar V; Weinstock C; Suzman DL; Agrawal S; Chang E; Anscher MS; Chi DC; Xu JX; Brewer JR; Brave MH; Hadadi M; Theoret MR; Kluetz PG; Goldberg KB; Ibrahim A; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L; Singh H
Lancet Oncol; 2021 Sep; 22(9):1230-1239. PubMed ID: 34310904
[TBL] [Abstract][Full Text] [Related]
18. A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer.
Maurice-Dror C; Le Moigne R; Vaishampayan U; Montgomery RB; Gordon MS; Hong NH; DiMascio L; Perabo F; Chi KN
Invest New Drugs; 2022 Apr; 40(2):322-329. PubMed ID: 34843005
[TBL] [Abstract][Full Text] [Related]
19. Proxalutamide in metastatic castration-resistant prostate cancer: Primary analysis of a multicenter, randomized, open-label, phase 2 trial.
Zhou T; Qin S; Xu W; Tang S; Chen G; Li S; Hou J; Gao X; Shi G; Sun Z; Jin J; Chen L; Sun W; Liu B; Wang J; Meng Q; Wang D; Hu Z; He D; Yang Y; Song X; Fu C; Wang Y; Ye D; Zhang W
Int J Cancer; 2023 Aug; 153(4):792-802. PubMed ID: 36919366
[TBL] [Abstract][Full Text] [Related]
20. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.
Corn PG; Heath EI; Zurita A; Ramesh N; Xiao L; Sei E; Li-Ning-Tapia E; Tu SM; Subudhi SK; Wang J; Wang X; Efstathiou E; Thompson TC; Troncoso P; Navin N; Logothetis CJ; Aparicio AM
Lancet Oncol; 2019 Oct; 20(10):1432-1443. PubMed ID: 31515154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]